As per DelveInsight, the Gastroesophageal Reflux Disease (GERD) Market is anticipated to grow immensely in the coming years owing to the rise in the number of prevalent cases of GERD patients, the rise in the healthcare spending across the world and the launch of the emerging therapies.
Key players, such as Phathom Pharmaceutical, Takeda, Sinorda Biomedicine, and others, are actively involved in developing drugs for Gastroesophageal reflux disease (GERD).
DelveInsight’s “Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastroesophageal Reflux Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Gastroesophageal Reflux Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Gastroesophageal Reflux Disease Overview
Gastroesophageal reflux disease (GERD) is a digestive ailment characterized by the retrograde flow of acidic stomach contents, food, and fluids from the stomach into the esophagus. GERD represents the chronic and persistent manifestation of this reflux.
Various intrinsic and structural mechanisms contribute to GERD, disrupting the esophagogastric junction barrier and exposing the esophagus to acidic gastric contents. While heartburn and regurgitation are typical clinical symptoms, GERD may also manifest with dysphagia, odynophagia, belching, epigastric pain, and nausea.
Several risk factors contribute to the development of GERD, including advancing age, elevated body mass index (BMI), smoking, anxiety or depression, and sedentary work patterns. Dietary habits, such as the acidity of consumed foods and the timing and portion size of meals, particularly before bedtime, also influence GERD occurrence.
Gastroesophageal Reflux Disease (GERD) Market Key Facts
-
As per Marco G Patti (2020), 25%-40% of Americans experience symptomatic GERD at some point, and about 7%-10% of Americans experience symptoms of GERD on a daily basis. Many individuals control their symptoms with over-the-counter (OTC) medications, and without consulting a medical professional, the actual number of individuals with GERD is probably higher.
-
As per Jorabar Singh Nirwan et al. (2020), GERD’s global prevalence was 13.98%, and 4.16% in China. Using the United Nations 2017 Revision of World Population Prospects, the estimated number of individuals suffering from GORD globally is 1.03 billion.
-
As per Wang et al. (2019), the prevalence of GERD (RE and NERD) was 17.3%, which was much higher in the ESCC population than 2.3% to 5.2% reported in the general Chinese population.
Gastroesophageal Reflux Disease (GERD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Gastroesophageal Reflux Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Gastroesophageal Reflux Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Gastroesophageal Reflux Disease (GERD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM). It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Gastroesophageal Reflux Disease (GERD) Epidemiology, Segmented as –
-
Prevalent Cases of Gastroesophageal reflux disease (GERD) in the 7MM
-
Diagnosed Cases of Gastroesophageal reflux disease (GERD) in the 7MM
-
Treated Cases of Gastroesophageal reflux disease (GERD) in the 7MM
-
Age-specific Prevalent Cases of Gastroesophageal reflux disease (GERD) in the 7MM
-
Gender-specific Prevalent Cases of Gastroesophageal reflux disease (GERD) in the 7MM
Gastroesophageal Reflux Disease (GERD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Gastroesophageal Reflux Disease market or expected to be launched during the study period. The analysis covers the Gastroesophageal Reflux Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gastroesophageal Reflux Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Gastroesophageal Reflux Disease Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market
Gastroesophageal Reflux Disease (GERD) Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Gastroesophageal Reflux Disease (GERD). Currently, Daewoong Pharmaceutical is leading the therapeutics market with its Gastroesophageal Reflux Disease (GERD) drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Gastroesophageal Reflux Disease (GERD) Therapeutics Market Include:
-
Addpharma
-
Chong Kun Dang Pharmaceutical
-
Cinclus Pharma
-
Daewoong Pharmaceutical
-
HK inno.N Corporation
-
Jeil Pharmaceutical
-
Jiangsu Sindora Biomedicine
-
Phathom Pharmaceuticals
-
Renexxion
-
Takeda
-
Trio Medicines
And Many Others
Emerging and Marketed Drugs in the Gastroesophageal Reflux Disease Therapeutics Market Include:
-
AD-214: Addpharma
-
Fexuprazan: Daewoong Pharmaceutical
-
IN-C002: HK inno.N
-
IN-C003: HK inno.N
-
JP-1366: Jeil Pharmaceuticals
-
Naronapride: Renexxion
-
Vonoprazan: Phathom Pharmaceuticals
-
X842: Jiangsu Sindora Biomedicine
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Gastroesophageal Reflux Disease Competitive Intelligence Analysis
4. Gastroesophageal Reflux Disease Market Overview at a Glance
5. Gastroesophageal Reflux Disease Disease Background and Overview
6. Gastroesophageal Reflux Disease Patient Journey
7. Gastroesophageal Reflux Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Gastroesophageal Reflux Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Gastroesophageal Reflux Disease Unmet Needs
10. Key Endpoints of Gastroesophageal Reflux Disease Treatment
11. Gastroesophageal Reflux Disease Marketed Products
12. Gastroesophageal Reflux Disease Emerging Drugs and Latest Therapeutic Advances
13. Gastroesophageal Reflux Disease Seven Major Market Analysis
14. Attribute Analysis
15. Gastroesophageal Reflux Disease Market Outlook (In US, EU5, and Japan)
16. Gastroesophageal Reflux Disease Access and Reimbursement Overview
17. KOL Views on the Gastroesophageal Reflux Disease Market
18. Gastroesophageal Reflux Disease Market Drivers
19. Gastroesophageal Reflux Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/